Mett, Vadim
Kurnasov, Oleg V.
Bespalov, Ivan A.
Molodtsov, Ivan
Brackett, Craig M.
Burdelya, Lyudmila G.
Purmal, Andrei A.
Gleiberman, Anatoli S.
Toshkov, Ilia A.
Burkhart, Catherine A.
Kogan, Yakov N.
Andrianova, Ekaterina L.
Gudkov, Andrei V. http://orcid.org/0000-0003-2548-0154
Osterman, Andrei L.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016056)
This work was supported by contracts from Cleveland BioLabs, Inc. to L.G.B and A.V.G. and from Genome Protection, Inc. to C.M.B. and A.V.G.
Article History
Received: 12 November 2020
Accepted: 11 March 2021
First Online: 12 April 2021
Competing interests
: The authors declare the following competing interests: A.V.G. is a shareholder of and consultant for Cleveland BioLabs, Inc. (CBLI) and Genome Protection, Inc. (GPI), companies that contributed to the development of entolimod and GP532. Research in Dr. Gudkov’s laboratory is supported by funding from both companies. A.L.O. is a consultant for GPI and the work of his laboratory on this project was supported by a research contract from Buffalo BioLabs. C.M.B. and L.G.B. have research contracts from GPI and CBLI, respectively. A.A.P., Y.N.K., and E.L.A. are consultants of GPI. All other authors declare no competing interests.